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Outline 
 The changing role of primary care 
• From inputs, process to outcomes 
 International trends in primary care 
performance 
 Lessons from national reforms 
• Paying for better performance in primary 
care 
 
 
The changing role of primary 
care 
 
Notes: the highest number of long-term conditions is restricted at 5. 
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No. of long-term conditions for people aged 50 and above
Ageing brings more chronic illness 
 % population 2014-15 2054-55 
Age 65-84 13% 18% 
Age 85 and over  2% 5% 
Changing health care needs 
Ageing populations and multiple comorbidities 
Source: Guthrie et al, 2011 
• greater complexities  
• greater costs 
• greater demands on primary 
care 
Changing needs, changing care 
 Preventing chronic disease over the life course? 
• Modifiable risk-factors (e.g. obesity) 
 Preventing an escalation of chronic diseases 
• Controlling and managing disease (e.g. keeping patients with 
diabetes healthy). 
 
 Changing health needs of patients with (multiple) 
chronic diseases: 
• Multiple health events requiring multidisciplinary care in a variety of 
setting 
• Patient, rather than disease, centred 
• Management and prevention 
 Placing greater focus on the performance of primary care 
• Beyond access, use and costs 
 
 
 
International trends in primary 
care performance 
 
Health expenditure: ambulatory care and offices 
of physicians – 2011 (or latest year) 
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Physician offices Ambulatory care
Source: OECD Health Statistics, 2014 
Trends in ambulatory care expenditure (2003-
2011 
Source: OECD Health Statistics, 2014 
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Remuneration of doctors, ratio to 
average wage, 2011 (or nearest year) 
Source: OECD, Health at Glance, 2013. 1. Physicians in training included (resulting in an underestimation). 2. 
Practice expenses included (resulting in an over-estimation). 3. Remuneration of self-employed physicians is 
net income rather than gross income (resulting in an underestimation). 4. Public sector employees only 
(resulting in an underestimation). 5. Specialists in training included (resulting in an underestimation). 
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Number of doctor consultations per capita, 
2011 (or nearest year) 
Source: OECD, Health at Glance, 2013.  
Asthma hospital admission in adults, 2006 
and 2011 (or nearest year) 
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COPD hospital admission in adults, 
2006 and 2011 (or nearest year) 
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Diabetes hospital admission in adults, 2006 
and 2011 (or nearest year) 
Source: OECD, Health at Glance, 2013.  
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Diabetes admissions per 1 000 patients 
with diabetes, 2011 (or nearest year)  
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Source: OECD, Cardiovascular disease and diabetes: better policies for better health care and outcomes, forthcoming.  
Comparing diabetes-related admissions and 
overall admissions across OECD countries 
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Source: OECD, Cardiovascular disease and diabetes: better policies for better health care and outcomes, forthcoming.  
Summary of international trends 
 Australia is in the middle of the OECD ‘pack’: expenditure, 
use and outcomes 
 But measuring primary care performance is complex:  
• Primary care systems encompass a myriad of activities and its 
functions differ considerably across countries.  
• Hampered by data infrastructure.  
• Differences in provider payment and contractual schemes across 
countries have an important effect on the scope of data collected.  
 Need for continues international R&D agenda to improve 
comparability  
 Benchmarking and monitoring activities of primary care are 
becoming more common (strongly related to reforms).  
Lessons from international 
reforms 
  
Policies to improve quality of care 
in primary care 
Policy type Examples 
Health system inputs 
(professionals, organisations, 
technologies) 
Accreditation and certification of health care institutes. 
Professional licensing including GPs and specialised nurses 
(e.g. diabetes or heart failure) and credentialing. Assessment 
and control of pharmaceutical products. 
Health system design (allocation 
of responsibilities) 
Accountability requirements at the primary care level. Quality 
governance structures in recognition of shifting focus of care 
towards primary care and social care. Quality as part of 
contracting and patient choice (competition). 
Monitoring (standards and 
information systems) 
National standards and guidelines. Regulation on public 
reporting (including policies and support for registries, use of 
administrative databases, electronic health records, data 
sharing across health sectors, and patient surveys). Audit 
studies. Integrated guidelines on chronic diseases. 
Improvement (incentive structures 
and programmes) 
Financial incentives such as pay for performance, care 
bundling, patient self-management.  
Source: OECD (2010), Improving value in health care: measuring quality, OECD Health Policy Studies, Paris 
The Disease Management Program (DMP)  
in Germany 
 DMP coverage:  
• Covers six disease (including diabetes mellitus Type 
1 and Type 2) 
• Voluntary participation of patients and physicians 
• Six million patients enrolled 
o  Diabetes mellitus Type 2 covering over 3 Million 
 Key aspects: 
• Physician based intervention  
• Patient activation and education  
• Treatment according to evidence-based guidelines  
• IT supported documentation, quality assurance 
• Mandatory evaluation of effectiveness and costs 
 
Accreditation of DMP 
 Regional health insurances make contracts 
with physicians  
 Federal Social Security Authority examines the 
contracts in the framework of the 
accreditation process 
 Health insurance funds get a lump sum for 
operational costs out of the health fund 
    (2012: 153 € per person, per year) 
 
 
Total program-associated costs 2012: 153 € per patient and year 
Costs of DMP 
doctors fee: 80 € 
coordination 
documentation 
doctors fee: 40 € 
patient education 
insurer: 33 € 
data management 
quality assurance 
patient information 
management costs 
Insurers are reimbursed with the real costs (153 €) from the health fund for all 
participants in accredited programs.  2012: approx. € 920 mn.    
Results from an observational 
study after 3 years:  
Mortality:  
•DMP: 11,3% 
•Non-DMP: 14,4% 
 
But care needs to be taken in 
interpreting this result  
 
Source: Miksch et al 2010, 
ELSID-Study (Fullerton et al., 
2012). 
 
Diabetes Type 2 - ELSID-Study (Sachsen-
Anhalt and Rheinland-Pfalz) 
 Evaluations show that DMPs has had a positive effect on: 
• physicians’ adherence to guidelines and process measures (annual eye exam 
increased from 70% to 83% Eichenlaub et al., 2004).  
• patients with blood sugar levels outside the target range fell from 8.5% to 
7.9% within a six-month period (Altenhofen et al., 2004). 
• Reduction in hospitalisations (Miksch et al., 2010).  
 Evidence on the programme’s impact on micro and macrovascular 
complications risk and costs was mixed 
 This may be explained by: 
• Evaluative complexity (observational data, issues of selection) 
• The programme’s impact on process measures whereby DMP participation 
led to intensified care. 
• Short follow-up period for some indicators 
o See: Ullrich et al., 2007; Stock et al, 2010,Stark et al., 2009; Fullerton et al., 2012. 
DMP Evaluations 
 Diabetes program launched  in 2007 expanded to  
COPD, heart failure and CVD risk-factors in 2010. 
 Health insurers negotiate a single annual fee with an 
entity (care group) to provide integrated care.   
 Care groups consists of multidisciplinary care providers 
(can subcontract)  
 Care group provides insurer with data on performance 
indicators for both process and outcomes, for example 
in diabetes: 
• percentage of patients who had foot examinations in the 
previous twelve months 
• percentage of patients whose blood sugar levels are under 
control 
o Rijken et al., 2008 
Bundled payments in the 
Netherlands 
 Still early days, but bundled payments have 
achieved: 
• integration of care sectors 
• transparency of delivered care 
• some indication of cost offsets with fewer 
hospitalisations 
  Challenges around: 
• Lack of competition among care groups 
• Negotiation powers of GPs 
• Development of integrated IT systems 
 
 
 
 
 
Bundled payments evaluations 
 
UK: Quality and Outcomes Framework 
 Incentives (money) to improve quality  
 Up to 30% of practice income linked to performance  
 Originally 147 indicators; 76 chronic disease 
 Evidence-based and measured by electronic records 
 From 2006, practices could achieve a max of 1000 
points, in clinical areas including CVD, diabetes,COPD 
epilepsy, hypothyroidism, cancer, palliative care, 
mental health, asthma, dementia, chronic kidney 
disease, obesity, learning disabilities and smoking.  
 
UK: Quality and Outcomes Framework 
 Points awarded in relation to level of 
achievement (e.g. % with diabetes with blood 
pressure below X mmHg)  
• 2004/5: £75/point 
• 2014/15: £156.92 England. £154.83 Wales. £133.47 Scotland. 
 Exception reporting 
 Total expenditure of around £1 billion per year. 
• Budget over-runs initially £1.1 billion in 2005/06 (£168 million 
over budget) 
UK QOF impact 
 Substantial improvements between 2005-2008 on indicators 
relating to diabetes, hypertension, stroke and heart disease 
[Eijkenaar et al. 2013] 
 Significant improvement in indicators after, but also before, QOF  
[Steele et al 2010; Calvert et al. 2009] 
 Quality of care increased before incentives, but increased faster 
afterwards for diabetes and asthma [Steele et al 2010] 
 Greater improvement 2002 to 2005 than 2005 to 2007 [Calvert et 
al. 2009] 
 No relationship between target achievement and outcomes such 
as hospital admissions and mortality [Eijkenaar et al 2013] 
Broader P4P questions 
 Many questions remain about P4P schemes: 
• the degree of real improvement  
• unintended consequences such as shifting away 
from non-incentive activities  
• aspects of design and implementation of the 
programs that are associated with their 
effectiveness 
• Are they a cost-effective way to achieve quality 
improvement? 
oCashin et al 2014 
P4P ten criteria for success (Eijkenaar 2011) 
 (1) defining performance broadly rather than narrowly; 
 (2) attention to patient selection and health-reducing substitution;  
 (3) include risk adjustment for outcome and resource use 
measures;  
 (4) involving providers in program design;  
 (5) favour group incentives over individual incentives;  
 (6) using either rewards or penalties depending on the context;  
 (7) more frequent, lower-powered incentives;  
 (8) absolute targets preferred over relative targets;  
 (9) multiple targets preferred over single targets; and  
 (10) permanent element of overall provider payment systems 
Key messages: 
 Changing needs, changing role of primary care 
• Beyond access and use and towards broader performance measures of quality  
 Internationally, Australia’s primary care system sits in the middle 
• Expenditure, output and outcomes 
 Take care with international comparisons 
• Primary care outputs and outcomes notoriously difficult to measure (even more so 
for international comparisons). 
• Outcome indicators related to many other factors, besides performance. 
• Factors such as disease prevalence, coding practices, health sector functions and 
financing confound performance measurers 
 Substantive reforms have had a positive impact but many unanswered 
questions remain 
 Data is the great enabler:  
• Advocacy, policy options, evaluation and program design 
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